Beris P
Département de Médecine Interne, Hôpital Cantonal, Genève.
Praxis (Bern 1994). 2004 Nov 10;93(46):1905-10. doi: 10.1024/0369-8394.93.46.1905.
Recombinant human erythropoietin (rHuEPO) and intravenous (i.v.) iron administration may be useful tools to save blood in surgery. In the perioperative period, rHuEPO should be used in slightly anemic patients for whom an autologous predonation program is not recommended (or feasible). In such cases, i.v. iron is only given if there is a functional or real iron deficiency state. In the post-operative period, i.v. iron is administered in association with rHuEPO in an attempt to rapidly correct severe post-operative anemia. The same regimen is used for patients undergoing surgery for inflammatory bowel disease and rheumatoid arthritis. Finally, other particular categories of patients, such as those with reduced body weight (< 50 kg), candidates for surgery with increased blood needs (> 5 units), or those with a too-short period of time before surgery, also benefit from the administration of these two drugs.
重组人促红细胞生成素（rHuEPO）和静脉注射铁剂可能是手术中节约用血的有用工具。在围手术期，对于不建议（或不可行）进行自体预存式献血计划的轻度贫血患者，应使用rHuEPO。在这种情况下，只有在存在功能性或真性缺铁状态时才给予静脉注射铁剂。在术后，静脉注射铁剂与rHuEPO联合使用，试图迅速纠正严重的术后贫血。对于接受炎症性肠病和类风湿关节炎手术的患者，采用相同的治疗方案。最后，其他特殊类别的患者，如体重减轻（<50kg）、手术需血量增加（>5单位）的手术候选人或手术前时间过短的患者，也受益于这两种药物的使用。
